Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis

Validating JADAS10 cut-off values for inactive disease, low disease and moderate disease activity levels in non-systemic juvenile idiopathic arthritis: a Finnish multicentre

Juvenile idiopathic arthritis (JIA) is the most common form of chronic arthritis in children and the most common cause of musculoskeletal disability in children. Early diagnosis may

Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6

A study was done to determine if the differentiation and activation phenotype of T cells in synovial fluid (SF) from patients with juvenile idiopathic arthritis (JIA) is associated

Background: To explore the effects of extracellular histones released by activated neutrophils on systemic-onset juvenile idiopathic arthritis (SoJIA), and to study the change of

We describe a girl with macrophage activation syndrome complicating systemic-onset juvenile arthritis who developed hyponatremia, hypophosphatemia, and hypouricemia associated with

While macrophage activation syndrome has occurred in soJIA patients on anakinra [19], our patient’s autopsy did not identify signs of severe systemic involvement outside of

MAS: Macrophage activation syndrome; MTX: Methotrexate; NSAID: Non- steroidal anti-inflammatory drug; oJIA: Oligoarticular JIA; pJIA: Polyarticular JIA; psJIA: Psoriatic JIA;